AbbVie continues immunology spree with $250M Celsius acquisition

AbbVie recently announced the acquisition of privately owned Celsius Therapeutics for $250 million in cash. This strategic buyout allows AbbVie to acquire a potentially first-in-class antibody targeting TREM1, which could be used to treat inflammatory bowel disease (IBD). "Given the potential relevance of TREM1 as a key driver of inflammation and pathology in IBD and other conditions, we are eager to advance the development of CEL383 with a goal of helping more patients with IBD achieve remission," said Kori Wallace, global head of immunology clinical development at AbbVie.

This acquisition is part of AbbVie's broader strategy to bolster its position in the immunology sector, especially as its flagship product, Humira (adalimumab), faces increasing competition from biosimilars. Celsius Therapeutics represents the sixth immunology-related transaction for AbbVie this year. Nevertheless, the most significant deal remains the recent licensing agreement with FutureGen Biopharmaceuticals for their anti-TL1A antibody, also aimed at treating IBD, which could be worth up to $1.7 billion.

CEL383, the antibody acquired from Celsius, recently completed a Phase I clinical trial that began last year. The study evaluated its safety, tolerability, and pharmacokinetics in healthy volunteers. TREM1, which is expressed on inflammatory monocytes and neutrophils, has been identified as a key player in the pathology of IBD. By acting upstream of several known inflammatory pathways, TREM1 amplifies inflammation, making it a promising target for new therapeutic interventions.

This acquisition underscores AbbVie's commitment to advancing treatments in the field of immunology, seeking to develop innovative therapies that could potentially bring relief to patients suffering from chronic inflammatory conditions like IBD. The company’s continuous investment in immunology reflects its strategic vision to remain a leader in this therapeutic area, diversifying its pipeline amidst the evolving competitive landscape.